At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,791 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
azelastineHcl 548 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Placebo, azelastineHcl, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 1,791 participants across 45 sites.
Detailed Summary
The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionJul 2009
TodayJul 2026
First PostedApr 17, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.2 years ago
Interventions
Placebodrug
Placebo
azelastineHcldrug
azelastine hydrochloride 548 mg
fluticasone propionatedrug
fluticasone propionate 200 mcg
azelastine Hcl/fluticasone propionatedrug
azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg